MANE
Veradermics, Inc
Next earnings ≈ Aug 11, 2026 · est. from filing cadence
Last earnings -3.9% on 2026-05-12
$119.37
▲ +1.77%$119.37▲ +216.21%
over 1Y
L $37.03EODHDH $119.37
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.8%
1W+27.2%
1M+16.5%
3M+76.7%
YTD+216.2%
1Y+216.2%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Strong Buy
Single-asset clinical-stage biotech with no revenue trading at ~6.9x IPO price — binary Phase 3 readout dominates everything.
Veradermics is a clinical-stage biopharma with zero product revenue, an accumulated deficit of $123.4M, and a single lead asset (VDPHL01, an extended-release oral minoxidil for pattern hair loss) carrying the entire equity story. FY2025 net loss widened to $70.0M from $26.5M (YoY -164.3%) as R&D scaled to $62.1M (+166.6%) ahead of two registration-directed trials. Operating cash burn of $71.6M against just $21.8M of cash at year-end would have been existential, but the 10-K discloses a Q4 2025 Series C raising $151.0M gross and a Q1 2026 IPO netting $269.7M at $17.00/share — together extending runway materially beyond the balance-sheet snapshot.
Sources: SEC EDGAR (CIK 0001827635, latest 10-Q filed 2026-05-12) · EODHD · analysis by claude-code · as of 6/25/2026, 12:45:29 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.